Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-06-14
2005-06-14
Horlick, Kenneth R. (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100
Reexamination Certificate
active
06905830
ABSTRACT:
This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.
REFERENCES:
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5660982 (1997-08-01), Tryggvason et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5846749 (1998-12-01), Slamon et al.
patent: 5876712 (1999-03-01), Cheever et al.
patent: 6027890 (2000-02-01), Ness et al.
patent: 801306 (1997-10-01), None
patent: 2711671 (1995-05-01), None
patent: WO 94/00764 (1994-01-01), None
patent: WO 94/09022 (1994-04-01), None
patent: WO 95/03428 (1995-02-01), None
patent: WO 96/31626 (1996-10-01), None
patent: WO 97/08343 (1997-03-01), None
patent: WO 98/02577 (1998-01-01), None
patent: WO 00/31534 (2000-02-01), None
Anastasi et al., “Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: linege, response to growth factor therapy, and clone expansion”Blood81(6), 1580-1585 (Mar. 15, 1993).
Anastasi, et al., “Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method”Blood79(7), 1796-1801 (Apr. 1, 1992).
Anatasi, et al., “Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acut lymphoblastic leukemia”Blood77(11), 2456-2462 (Jun. 1, 1991).
Anastasi, et al., “The relationship between secondary chromosomal abnormalities and blast tranformation in chronic myelogenous leukemia”Leukemia9(4), 628-633 (Apr. 1995).
Clark, et al., “Follow-up study of HER-2
ew amplification in primary breast cancer”Cancer Research51(3); 944-948 (Feb. 1, 1991).
DAKO Corporation, “DAKO Anti-HER2 IHC System for Immunoenzymatic Staining” (Packaging Insert) pps. 1-12.
Fendly, et al., “Characterization of Murine Momoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
ew Gene Product”Cancer Research, 50, 1550-1558 (Mar. 1, 1990).
Heintz, et al., “Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcionoma”Archives Of Pathology&Laboratory Medicine, 114(2), 160-163 (Feb. 1990).
Jenkins, et al., “Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens”Blood, 79(12), 3307-3315 (Jun. 15, 1992).
Kury, et al., “HER-2 oncogene amplification and overall survival of breast carcinoma patients”European Journal of Cancer, 26(9), 946-949 (1990).
McCann, et al., “Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer”Cancer Research, 51(12), 3296-3303 (Jun. 15, 1991).
Nelson, et al., “Comparison of HER-2/NEU Amplification Using Fluorescent In Situ Hybridization (FISH) with Immunohistochemically Determined Overexpression in Breast Cancers”Modern Pathology, 9(1), 21A (1996).
Paterson et al., “Correlation between c-erb-2 amplification and rish of recurrent disease in node-negative breast cancer”Cancer Research, 51(2), 556-567 (Jan. 15, 1991).
Pauletti et al., “Detection and quantitation of HER-2
eu gene amplification in human breast cancer archival material using fluorescence in situ hybridization”Oncogene13(1), 63-72 Jul. 4, 1996.
Ravdin et al., Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancerJournal Of Clinical Oncology, 12(3), 467-474 (Mar 1994).
Slamon, et al., “Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
ew Oncogene”Science, 235, 177-182 (1987).
Slamon, et al., “Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer”Science, 244, 707-712 (May 1989).
Tandon et al., “HER-2
eu oncogene protein and prognosis in breast cancer”Journal of Clinical Oncology, 7(8), 1120-1128 (Aug. 1989).
van de Vijver, et al, “Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer”New England J. of Medicine, 319(19), 1239-1245 (Nov. 10, 1988).
van Lom et al., “In situ hybridization on May-Grunwald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allows detection of cell-lineage-specific cytogenetic abnormalities”Blood, 82(3), 884-888 (Aug. 1, 1993).
Walker, et al., “An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer”British Journal of Cancer, 60(3), 426-429 (Sep. 1989).
Winstanley et al., “The long term prognostic significance of c-erbB-2 in primary breast cancer”British Journal of Cancer, 63(3), 447-450 (Mar. 1991).
Wolman, et al., “An approach to definition of genetic alterations in prostate cancer”Diagnostic Molecular Pathology, 1(3), 192-199 (Sep. 1992).
Wright, et al., “Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer”Cancer Research, 49(8), 2087-2090 (Apr. 15, 1989).
Young et al., “Species-specific in situ hybridization with fluorochrome-labeled DNA probes to study vascularization of human skin grafts on athymic mice”Journal of Burn Care&Rehabilitation, 17(4), 305-310 (Jul.-Aug. 1996).
Zhou et al., “Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of desease”Oncogene, 4(1), 105-108 (Jan. 1989).
Zitzelsberger, et al., “Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in situ hybridization (FISH) on paraffin-embedded tissue sections with centromere-specific DNA probes”Journal of Pathology, 172(4), 325-335 (Apr. 1994).
Ng, et al., “Short Communication—Combined Morphological and Interphase Fluorescence in Situ Hybridization Study in Multiple Myeloma of Chinese Patients”American Journal of Pathology, 154, 15-22 (1999).
Gardiner, et al., “Development of a technique that allows simultaneous assessment of morphology and gene amplification by FISH: application to HER-2/Neu amplification in breast cancer”Modern Pathology, (abstract #1122) 12(1), 191A (Jan. 1999).
Press, et al., “Amplification and overexpression of HER-2
eu in carcinomas of the salivary gland: correlation with poor prognosis”Cancer Research, 54(21), 5675-5682 (Nov. 1, 1994).
Ratcliffe et al., “The combination of in situ hybridization and immunohistochemical analysis: and evaluation of Her2
eu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium”Modern Pathology, 10(12), 1247-1252 (Dec. 1997).
Cohen Robert L.
Gardiner Mary Beth
Sliwkowski Mark X.
Stelzer Gregory T.
Dreger Ginger R.
Esoterix, Inc.
Fox James A.
Genentech Inc.
Heller Ehrman White & McAuliffe LLP
LandOfFree
Tissue analysis and kits therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue analysis and kits therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue analysis and kits therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3484553